2024
DOI: 10.1136/rmdopen-2023-003531
|View full text |Cite
|
Sign up to set email alerts
|

Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System

Hugo Jourdain,
Léa Hoisnard,
Emilie Sbidian
et al.

Abstract: ObjectivesBiosimilar-originator equivalence has been demonstrated in phase 3 trials in a few indications of infliximab, etanercept and adalimumab. The objective of our study was to compare the persistence and safety of biosimilars versus originators in all the licensed indications of these molecules.MethodsWe used data from the French National Health Data System (SNDS), covering 99% of the French population, to identify infliximab, etanercept and adalimumab initiators from biosimilar launch (January 2015, May … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 46 publications
0
2
0
Order By: Relevance
“… 3 In addition, considering the implications of treatment discontinuation and implementing strategies to address them in the algorithm design will enhance its applicability in real-world clinical settings. 4 Finally, collaborating with healthcare providers and stakeholders to validate the algorithm’s performance in diverse patient populations and healthcare settings can strengthen its generalizability and utility.…”
Section: Dear Editormentioning
confidence: 99%
See 1 more Smart Citation
“… 3 In addition, considering the implications of treatment discontinuation and implementing strategies to address them in the algorithm design will enhance its applicability in real-world clinical settings. 4 Finally, collaborating with healthcare providers and stakeholders to validate the algorithm’s performance in diverse patient populations and healthcare settings can strengthen its generalizability and utility.…”
Section: Dear Editormentioning
confidence: 99%
“…3 In addition, considering the implications of treatment discontinuation and implementing strategies to address them in the algorithm design will enhance its applicability in real-world clinical settings. 4 Finally, collaborating with…”
mentioning
confidence: 99%